Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis
D. Vinson, L. Molet-Benhamou, Yannick Degboé, A. den Broeder, F. Ibrahim, C. Pontes, R. Westhovens, J. Závada, T. Pham, T. Barnetche, A. Constantin, Adeline Ruyssen-Witrand
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.